CStone Pharmaceuticals
CSPHFOTCHealthcare● Active
$0.70
+$0.00(+0.00%)
Market Cap$1.1B
P/E Ratio—
52W High$1.01
52W Low$0.518
CStone Pharmaceuticals (CSPHF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CSPHF · earnings · updated Jun 8, 2026
Latest Earnings
Q1 FY2026Report Date: Mar 26, 2026EPS Actual
-$0.02
Est. -$0.01 · -140.0%
Revenue
$0.03B
Est. $0.03B · +5.9%
Fiscal Period
Q1 FY2026
FY ends December
Report Date
Mar 26, 2026
After Market Close
▼ Miss EPS▲ Beat Revenue
CSPHF reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.07
Rev. $15.39B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.07
Rev. Est.$15.39B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 20, 2026 | -$0.03 | — | — | — | $0.02B | — |
| ▼ Q1 FY2026 | Mar 26, 2026 | -$0.01 | -$0.02 | -140.0% | $0.03B | $0.03B | +5.9% |
| ◌ Q1 FY2026 | Mar 25, 2026 | -$0.13 | — | — | — | $0.03B | — |
| ▼ Q3 FY2025 | Aug 14, 2025 | -$0.01 | -$0.01 | -2.7% | $0.00B | $0.02B | -77.1% |
| ▼ Q1 FY2025 | Mar 25, 2025 | -$0.00 | -$0.01 | -166.7% | $0.02B | $0.04B | -51.4% |
| — Q4 FY2024 | Dec 31, 2024 | — | -$0.01 | — | $0.02B | — | — |
| ▲ Q3 FY2024 | Aug 23, 2024 | -$0.01 | $0.00 | +112.3% | $0.03B | $0.04B | -17.7% |
| ▼ Q1 FY2024 | Mar 27, 2024 | -$0.01 | -$0.02 | -30.0% | $0.03B | $0.05B | -45.8% |
Q3 FY2026
Aug 20, 2026
EPS Actual
—
EPS Est.
-$0.03
EPS Surpr.
—
Revenue
—
Q1 FY2026
Mar 26, 2026Miss
EPS Actual
-$0.02
EPS Est.
-$0.01
EPS Surpr.
-140.0%
Revenue
$0.03B
Q1 FY2026
Mar 25, 2026
EPS Actual
—
EPS Est.
-$0.13
EPS Surpr.
—
Revenue
—
Q3 FY2025
Aug 14, 2025Miss
EPS Actual
-$0.01
EPS Est.
-$0.01
EPS Surpr.
-2.7%
Revenue
$0.00B
Q1 FY2025
Mar 25, 2025Miss
EPS Actual
-$0.01
EPS Est.
-$0.00
EPS Surpr.
-166.7%
Revenue
$0.02B
Q4 FY2024
Dec 31, 2024
EPS Actual
-$0.01
EPS Est.
—
EPS Surpr.
—
Revenue
$0.02B
Q3 FY2024
Aug 23, 2024Beat
EPS Actual
$0.00
EPS Est.
-$0.01
EPS Surpr.
+112.3%
Revenue
$0.03B
Q1 FY2024
Mar 27, 2024Miss
EPS Actual
-$0.02
EPS Est.
-$0.01
EPS Surpr.
-30.0%
Revenue
$0.03B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-0.11 | $-0.11 | $-0.11 | 1 |
| Q3 FY2028 | $-0.19 | $-0.19 | $-0.19 | 1 |
| Q2 FY2028 | $-0.05 | $-0.05 | $-0.05 | 1 |
| Q1 FY2028 | $-0.10 | $-0.10 | $-0.10 | 1 |
| Q4 FY2027 | $-0.03 | $-0.03 | $-0.03 | 1 |
| Q3 FY2027 | $-0.09 | $-0.09 | $-0.09 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.3B | $0.3B | $0.3B | 1 |
| Q3 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q2 FY2028 | $0.2B | $0.2B | $0.2B | 1 |
| Q1 FY2028 | $0.1B | $0.1B | $0.1B | 1 |
| Q4 FY2027 | $0.3B | $0.3B | $0.3B | 1 |
| Q3 FY2027 | $0.3B | $0.3B | $0.3B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q1 FY2026 | Mar 26, 2026 | -140.0% | $0.88 | $0.88 | +0.06% |
| ▼ Q3 FY2025 | Aug 14, 2025 | -2.7% | $0.86 | $0.86 | +0.00% |
| ▼ Q1 FY2025 | Mar 25, 2025 | -166.7% | $0.52 | $0.52 | +0.00% |
| — Q4 FY2024 | Dec 31, 2024 | — | $0.23 | $0.23 | +0.00% |
| ▲ Q3 FY2024 | Aug 23, 2024 | +112.3% | $0.19 | $0.19 | +0.00% |
| ▼ Q1 FY2024 | Mar 27, 2024 | -30.0% | $0.12 | $0.12 | +0.50% |
| — Q1 FY2024 | Jan 17, 2024 | — | $0.32 | $0.32 | +0.00% |
| ▲ Q2 FY2023 | Jun 30, 2023 | +42.3% | No price data | $0.47 | — |
Q1 FY2026+0.06%
Report Date
Mar 26, 2026
EPS Beat/Miss
-140.0%
Price Before
$0.88
Price After
$0.88
Q3 FY2025+0.00%
Report Date
Aug 14, 2025
EPS Beat/Miss
-2.7%
Price Before
$0.86
Price After
$0.86
Q1 FY2025+0.00%
Report Date
Mar 25, 2025
EPS Beat/Miss
-166.7%
Price Before
$0.52
Price After
$0.52
Q4 FY2024+0.00%
Report Date
Dec 31, 2024
EPS Beat/Miss
—
Price Before
$0.23
Price After
$0.23
Q3 FY2024+0.00%
Report Date
Aug 23, 2024
EPS Beat/Miss
+112.3%
Price Before
$0.19
Price After
$0.19
Q1 FY2024+0.50%
Report Date
Mar 27, 2024
EPS Beat/Miss
-30.0%
Price Before
$0.12
Price After
$0.12
Q1 FY2024+0.00%
Report Date
Jan 17, 2024
EPS Beat/Miss
—
Price Before
$0.32
Price After
$0.32
Q2 FY2023—
Report Date
Jun 30, 2023
EPS Beat/Miss
+42.3%
Price Before
—
Price After
$0.47
Avg Beat Reaction+0.00%
Avg Miss Reaction+0.14%
Beat Rate2 / 8 quarters
Largest Move+0.50% (Q1 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CSPHF ends December
CStone Pharmaceuticals (CSPHF) most recently reported earnings on March 26, 2026 for Q1 FY2026, posting EPS of $-0.02 — missing the analyst consensus of $-0.01 by -140.0%. The next CSPHF earnings date is expected around September 1, 2026.
Each quarter, investors track CSPHF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CSPHF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CSPHF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CSPHF earnings · 5 questionsCStone Pharmaceuticals's next earnings report is expected around September 1, 2026. CSPHF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CSPHF historically reports after market close (AMC).
CSPHF earnings datewhen is CSPHF earningsCSPHF next earnings datewhen does CSPHF report earningsCSPHF earnings calendar
▸ Source: FMP · CStone Pharmaceuticals SEC filings · US GAAP · CStone Pharmaceuticals SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026